Want to see TXG full AI Analyst Report?
Total Valuation
10x Genomics has a market cap or net worth of $4.67B. The enterprise value is $3.67B.
Market Cap$4.67B
Enterprise Value$3.67B
Share Statistics
10x Genomics has 116,877,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding116,877,320
Owned by Insiders2.48%
Owned by Institutions33.22%
Financial Efficiency
10x Genomics’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -12.34%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-12.34%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee492.21K
Profits Per Employee-33.34K
Employee Count1,306
Asset Turnover0.62
Inventory Turnover3.53
Valuation Ratios
The current PE Ratio of 10x Genomics is ―. 10x Genomics’s PEG ratio is 0.61.
PE Ratio―
PS Ratio3.17
PB Ratio2.56
Price to Fair Value2.56
Price to FCF15.64
Price to Operating Cash Flow38.55
PEG Ratio0.61
Income Statement
In the last 12 months, 10x Genomics had revenue of 642.82M and earned -43.54M in profits. Earnings per share was -0.35.
Revenue642.82M
Gross Profit443.88M
Operating Income-110.89M
Pretax Income-39.91M
Net Income-43.54M
EBITDA3.91M
Earnings Per Share (EPS)-0.35
Cash Flow
In the last 12 months, operating cash flow was 127.82M and capital expenditures -5.64M, giving a free cash flow of 122.18M billion.
Operating Cash Flow127.82M
Free Cash Flow122.18M
Free Cash Flow per Share1.05
Dividends & Yields
10x Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.46
52-Week Price Change217.91%
50-Day Moving Average26.36
200-Day Moving Average19.62
Relative Strength Index (RSI)68.93
Average Volume (3m)3.20M
Important Dates
10x Genomics upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
10x Genomics as a current ratio of 4.46, with Debt / Equity ratio of 9.99%
Current Ratio4.46
Quick Ratio4.09
Debt to Market Cap0.04
Net Debt to EBITDA-80.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, 10x Genomics has paid 3.64M in taxes.
Income Tax3.64M
Effective Tax Rate-0.09
Enterprise Valuation
10x Genomics EV to EBITDA ratio is 439.61, with an EV/FCF ratio of 13.21.
EV to Sales2.67
EV to EBITDA439.61
EV to Free Cash Flow13.21
EV to Operating Cash Flow12.63
Balance Sheet
10x Genomics has $539.85M in cash and marketable securities with $81.39M in debt, giving a net cash position of $458.46M billion.
Cash & Marketable Securities$539.85M
Total Debt$81.39M
Net Cash$458.46M
Net Cash Per Share$3.92
Tangible Book Value Per Share$5.85
Margins
Gross margin is 69.60%, with operating margin of -17.25%, and net profit margin of -6.77%.
Gross Margin69.60%
Operating Margin-17.25%
Pretax Margin-6.21%
Net Profit Margin-6.77%
EBITDA Margin0.61%
EBIT Margin-6.21%
Analyst Forecast
The average price target for 10x Genomics is $25.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.75
Price Target Upside-1.27% Downside
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast2.26%
EPS Growth Forecast86.67%